Compare ROG & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROG | AMLX |
|---|---|---|
| Founded | 1832 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1994 | 2021 |
| Metric | ROG | AMLX |
|---|---|---|
| Price | $159.26 | $17.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $133.00 | $21.56 |
| AVG Volume (30 Days) | 300.4K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $879,091,000.00 | $380,786,000.00 |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $6.09 | N/A |
| P/E Ratio | $668.36 | ★ N/A |
| Revenue Growth | 7.07 | ★ 1612.94 |
| 52 Week Low | $61.17 | $5.98 |
| 52 Week High | $169.00 | $18.74 |
| Indicator | ROG | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 72.95 |
| Support Level | $98.08 | $12.17 |
| Resistance Level | N/A | $18.61 |
| Average True Range (ATR) | 6.89 | 0.98 |
| MACD | 0.61 | 0.42 |
| Stochastic Oscillator | 68.52 | 81.86 |
Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.